# Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

> **NCT01010633** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 406 (actual)

## Conditions studied

- Inflammation
- Pain

## Interventions

- **DRUG:** Vehicle of Loteprednol Etabonate
- **DRUG:** Loteprednol Etabonate

## Key facts

- **NCT ID:** NCT01010633
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-08
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2012-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010633, "Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01010633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*